Should Induction Chemotherapy Be Considered First‐Line Therapy for Sinonasal Undifferentiated Carcinoma?
The Laryngoscope · 2026-03 · 136 (3) · 1047-1049
DOI: 10.1002/lary.32361 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, online erschienen am 20.06.2025. Verfasst von Daniel X Ma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Rush Medical College, Rush University Medical Center, Chicago, Illinois, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Rush Medical College, Rush University Medical Center, Chicago, Illinois, USA.
- Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Otorhinolaryngology-Head and Neck Surgery, Rush University Medical Center, Chicago, Illinois, USA.
- Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine, California, USA.
ORCID-Profile: Daniel X Ma, Edward C Kuan
Zitieren
APA
Ma, D. X., Su, S. Y., Tajudeen, B. A., & Kuan, E. C. (2026). Should Induction Chemotherapy Be Considered First‐Line Therapy for Sinonasal Undifferentiated Carcinoma?. The Laryngoscope, 136(3), 1047-1049. https://doi.org/10.1002/lary.32361
Vancouver
Ma DX, Su SY, Tajudeen BA, Kuan EC. Should Induction Chemotherapy Be Considered First‐Line Therapy for Sinonasal Undifferentiated Carcinoma?. The Laryngoscope. 2026;136(3):1047-1049. doi:10.1002/lary.32361
BibTeX
@article{Ma2026,
author = {Ma, Daniel X and Su, Shirley Y and Tajudeen, Bobby A and Kuan, Edward C},
title = {Should Induction Chemotherapy Be Considered First‐Line Therapy for Sinonasal Undifferentiated Carcinoma?},
journal = {The Laryngoscope},
year = {2026},
volume = {136},
number = {3},
pages = {1047--1049},
doi = {10.1002/lary.32361}
}
EUVIMED